Completed PHASE3 INTERVENTIONAL 2-arm NCT00415805

Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent

A Pilot, Open-label, Multicenter Intra-individual Comparison of Multihance and Vasovist for Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) of Renal Arteries

Sponsor: Bracco Diagnostics, Inc

Conditions Steno-occlusive Disease

Interventions Multihance vasovist

Updated 6 times since 2017 Last updated: Jul 31, 2023 Started: Dec 31, 2006 Primary completion: Dec 31, 2008 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00415805, this PHASE3 trial focuses on Steno-occlusive Disease and remains completed. Sponsored by Bracco Diagnostics, Inc, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2023 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bracco Diagnostics, Inc

Data source: Bracco Diagnostics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy